Survival Times of Triple-Negative Breast Cancer Patients Based on Treatment Type: A Comparative Nonparametric Survival Analysis

Saidu; Hindatu; James; Tolulope Olayemi; Muazu; S.B.3; Umar; A.4; Corresponding author

doi:10.56201/ijasmt.vol.12.no4.2026pg50.56

📄 Download Paper

Survival Times of Triple-Negative Breast Cancer Patients Based on Treatment Type: A Comparative Nonparametric Survival Analysis

Saidu, Hindatu, James, Tolulope Olayemi, Muazu, S.B.3, Umar, A.4, Corresponding author

Abstract

Triple-negative breast cancer is an aggressive subtype of breast cancer associated with poor prognosis and limited treatment options. Survival outcomes among TNBC patients are known to vary depending on the type of treatment received, making comparative survival evaluation essential for clinical decision-making. This study aimed to assess and compare the survival times of TNBC patients based on different treatment types, including chemotherapy, radiotherapy, surgery, and combination therapy. Survival data from 100 TNBC patients were analyzed using nonparametric survival techniques. Differences in survival distributions across treatment groups were evaluated using the Log-Rank (Mantel–Cox), Breslow (Generalized Wilcoxon), and Tarone– Ware tests. Among patients who received chemotherapy (30 patients), 22 deaths and 8 censored cases were recorded, yielding the lowest survival rate of 26.7%. Radiotherapy patients (23 patients) experienced 12 deaths and 11 censored cases, with a survival rate of 47.8%. Surgery produced the most favorable outcome, with 9 deaths and 13 censored cases among 22 patients, resulting in a survival rate of 59.1%. Combination therapy showed 15 deaths and 10 censored cases among 25 patients, corresponding to a survival rate of 40.0%. Overall, 58 deaths and 42 censored cases were observed across all treatments. All three statistical tests indicated significant differences in survival outcomes by treatment type (p < 0.05). The study demonstrates that survival outcomes among TNBC patients differ significantly according to treatment type. Surgical intervention was associated with the highest survival rate in this cohort, highlighting the importance of treatment selection, early detection, and appropriate therapeutic strategies in improving TNBC survival outcomes.

Keywords

Triple-negative breast cancerTreatment typeSurvival analysisLog-rank testCensored data

References

Adebamowo, C. A., Ogundiran, T. O., & Fagbemi, A. F. (2021). Breast cancer in sub-Saharan Africa: Epidemiology, challenges, and opportunities. The Lancet Oncology, 22(11), e487– e498. https://doi.org/10.1016/S1470-2045(21)00412-5 Bianchini, G., De Azambuja, E., & Loibl, S. (2022). Triple-negative breast cancer: Recent therapeutic advances and future directions. Nature Reviews Clinical Oncology, 19(10), 645–660. https://doi.org/10.1038/s41571-022-00668-6 Foulkes, W. D., Bierie, B., & Polyak, K. (2010). Triple-negative breast cancer: Distinctive features and targeted therapies. Nature Reviews Cancer, 10(12), 868–879. https://doi.org/10.1038/nrc2948 Gandhi, S., Spring, L. M., & Waks, A. G. (2023). Survival disparities in triple-negative breast cancer by treatment modality and stage at diagnosis. Breast Cancer Research and Treatment, 198(2), 321–332. https://doi.org/10.1007/s10549-023-06891-4 Jedy-Agba, E., Curado, M. P., Ogunbiyi, O., Adebamowo, S. N., & Odukoya, O. (2020). Cancer incidence in Nigeria: A report from the population-based cancer registry. Cancer Epidemiology, 68, 101778. https://doi.org/10.1016/j.canep.2020.101778 Kleinbaum, D. G., & Klein, M. (2012). Survival analysis: A self-learning text (3rd ed.). Springer. https://doi.org/10.1007/978-1-4419-6646-9 Li, X., Yang, J., Peng, L., Sahin, A. A., Huo, L., Ward, K. C., & O’Regan, R. M. (2023). Molecular heterogeneity and therapeutic targeting in triple-negative breast cancer. Cancer Research, 83(5), 678–690. https://doi.org/10.1158/0008-5472.CAN-22-2891 Loibl, S., Poortmans, P., & Untch, M. (2023). Neoadjuvant chemotherapy and surgery in triple- negative breast cancer: Optimizing sequence and timing. The Lancet Oncology, 24(4), e168–e179. https://doi.org/10.1016/S1470-2045(23)00089-1 McGale, P., Taylor, C., Correa, C., Cutter, D., Duane, F., Ewertz, M., & Early Breast Cancer Trialists’ Collaborative Group. (2014). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality. The Lancet, 383(9935), 2127–2135. https://doi.org/10.1016/S0140-6736(14)60488-8 Mittendorf, E. A., Tamir, I. J., & Morrow, M. (2022). Surgical management of triple-negative breast cancer: Timing, extent, and survival implications. Annals of Surgical Oncology, 29(4), 2345–2356. https://doi.org/10.1245/s10434-021-01089-9 Ogundiran, T. O., Ademola, A. F., & Adebamowo, C. A. (2021). Delayed presentation and treatment access barriers for breast cancer in Nigeria: A health systems analysis. Journal of Global Oncology, 7, 112–123. https://doi.org/10.1200/GO.20.00214 Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Orvieto, E., & Dent, R. (2020). Pembrolizumab for early triple-negative breast cancer. New England Journal of Medicine, 382(9), 810–821. https://doi.org/10.1056/NEJMoa1910542 Spring, L. M., Fell, G., Arfe, A., Sharma, C., Greenup, R., Reynolds, C., & Winer, E. P. (2022). Management of triple-negative breast cancer: Current standards and future directions. Journal of Clinical Oncology, 40(15), 1678–1690. https://doi.org/10.1200/JCO.21.02345 Therneau, T. M., & Grambsch, P. M. (2000). Modeling survival data: Extending the Cox model. Springer. https://doi.org/10.1007/978-1-4757-3294-8 Waks, A. G., & Winer, E. P. (2019). Breast cancer treatment: A review. JAMA, 321(3), 288–300. https://doi.org/10.1001/jama.2018.20710

Survival Times of Triple-Negative Breast Cancer Patients Based on Treatment Type: A Comparative Nonparametric Survival Analysis

Abstract

Keywords

References

More Articles from INTERNATIONAL JOURNAL OF APPLIED SCIENCES AND MATHEMATICAL THEORY